Genetic Lusitropic Therapy: Modulation of SERCA2a in HFpEF

Time: 4:15 pm
day: Day One


  • The role of SERCA2a on calcium trafficking, ventricular relaxation (lusitropy) and the complex mechanisms of diastolic dysfunction in HFpEF will be discussed
  • Description of the evidence for lusitropic improvement via enhancement of SERCA2a activity in animal models of HFpEF
  • Presentation of the design of the first gene therapy trial in HFpEF patients to enhance the expression of SERCA2a